One‐year change in radiographic joint space width in patients with unilateral joint space narrowing: Data from the osteoarthritis initiative

Objective To examine the rate of joint space width (JSW) loss in both knees of patients with unilateral medial joint space narrowing (JSN) at baseline. Methods Cases were selected from a pool of 2,678 subjects enrolled in the Osteoarthritis Initiative cohort. Inclusion criteria for the present study...

Full description

Saved in:
Bibliographic Details
Published inArthritis care & research (2010) Vol. 62; no. 7; pp. 924 - 931
Main Authors Benichou, O. D., Hunter, D. J., Nelson, D. R., Guermazi, A., Eckstein, F., Kwoh, K., Myers, S. L., Wirth, W., Duryea, J.
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.07.2010
Subjects
Online AccessGet full text
ISSN2151-464X
2151-4658
2151-4658
DOI10.1002/acr.20149

Cover

More Information
Summary:Objective To examine the rate of joint space width (JSW) loss in both knees of patients with unilateral medial joint space narrowing (JSN) at baseline. Methods Cases were selected from a pool of 2,678 subjects enrolled in the Osteoarthritis Initiative cohort. Inclusion criteria for the present study were unilateral medial JSN, bilateral frequent knee pain, and body mass index (BMI) ≥25 kg/m2. Baseline and 1‐year fixed flexion radiographs of both knees were read (blinded to time point) using an automated algorithm for minimum JSW and JSW at 4 fixed locations in the medial compartment. Results Sixty‐seven participants met the inclusion criteria: 43 women and 24 men, with mean ± SD age 60 ± 9 years and mean ± SD BMI 31 ± 4 kg/m2. Thirty‐seven subjects (55%) had ≥1 definite tibiofemoral osteophyte. The average progression in no‐JSN knees was comparable with that in JSN knees (approximately −0.2 mm/year). However, JSW change was more variable in no‐JSN knees, resulting in standardized response means (SRMs; the mean/SD) of approximately −0.24 in no‐JSN knees versus approximately −0.41 in JSN knees on average at the 4 fixed locations, and SRMs of −0.24 and −0.35, respectively, for minimum JSW. Young age and high BMI were associated with increased progression, especially in JSN knees. Conclusion JSN and no‐JSN knees progressed at a comparable rate, but a wider distribution of JSW change in no‐JSN knees resulted in a poorer sensitivity to change in these knees.
Bibliography:Dr. Duryea has received consultancies, speaking fees, and/or honoraria from Cleveland Clinic, State University of New York at Buffalo, Tufts Medical Center, and Chondrometrics GmbH (less than $10,000 each) and from Merck (more than $10,000).
Drs. Benichou and Myers have stock ownership or options in Eli Lilly.
Dr. Guermazi has received consultancies, speaking fees, and/or honoraria from Genzyme and Facet Solutions (less than $10,000 each) and from Stryker and Merck Serono (more than $10,000 each), has stock ownership or options in Synarc, and is the president of Boston Imaging Core Lab.
Dr. Kwoh has received grant funding from AstraZeneca.
Dr. Eckstein has received consultancies, speaking fees, and/or honoraria from Wyeth, Genzyme, Aventis, and GlaxoSmithKline (less than $10,000 each) and from Pfizer, Novartis, and MerckSerono (more than $10,000 each), and has stock co‐ownership in Chondrometrics GmbH.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:2151-464X
2151-4658
2151-4658
DOI:10.1002/acr.20149